The chairman of the Board of the Cancer Center criticizes Dr. Top, who says he "crossed lines"
The chairman of the Board of the Cancer Center criticizes Dr. Top, who says he "crossed lines"
This article was produced in association with The New York Times.
The chairman of the board of directors of Memorial Sloan Kettering Cancer Center openly discredited the hospital's former medical director on Monday, telling hospital staff he had "crossed the lines" and had "left the reservation" in his external relations with the health and pharmaceutical companies.
The comments of Douglas A. Warner III, the chairman of the center's board of directors and supervisors, as well as Dr. Craig B. Thompson, the executive director, went beyond the hospital's previous statements about the former medical director, Dr. José Baselga. . Until Monday, the hospital had said that it followed internal policies and that, mainly, it had not revealed its affiliations in the industry in some articles of medical journals.
"I have to say that, although we put in a lot of effort and argue a lot, we were not as effective as we should have been," Warner said. according to a preliminary transcript from a meeting with hospital staff that was inadvertently emailed to a New York Times reporter. "He crossed the lines that we should have done more to stop us."
Baselga did not respond to phone calls or an email requesting comments.
Monday's meeting between hospital executives and their employees is the latest in a series conducted by the cancer center, as it carries out a comprehensive review of the policies on the links of the non-profit institution with external industries. Memorial Sloan Kettering has been forced to reexamine the rules governing the memberships and compensations of the board following the articles of The Times and ProPublica that revealed inside information about new companies that were prepared to harvest millions of dollars for advances in treatments. against cancer and biotechnological advances.
The hospital's top executives have come under scrutiny in recent weeks, prompting Warner to question Monday whether Thompson would be allowed to continue on the board of Merck, which produces the cancer drug, the box office success Keytruda. In addition to Merck, Thompson is also the director of Charles River Laboratories, a publicly traded company that helps research early drug development.
Thompson received $ 300,000 in compensation from Merck in 2017, According to the financial presentations of the company.. They paid him $ 70,000 in cash. of the Charles River in 2017, plus $ 215,050 in stock. The compensation for the two corporate boards was in addition to what he was paid as CEO of Memorial Sloan Kettering. In 2016, he earned $ 6.7 million in total compensation from the cancer center and related organizations, according to the most recent Declarations of the Internal Revenue Service.
Should Craig still be sitting on Merck's advice? We do not have a policy on that, "Warner said during the meeting, explaining that he had discussed the board's membership with Thompson when he joined the hospital in 2010. And although it was seen as" something good, "Warner added that" we need "to give one step behind that now and ask if that is still appropriate, if appropriate in the future. "
In a memo at the end of last week and again at Monday's meeting, the New York-based cancer center emphasized the need to revise its policies, which had not addressed some of the possible conflicts that had recently become public. At a time when investors are launching large amounts of money in startups developing promising treatments.
Thompson said Monday that working with for-profit companies remained a priority. "We can not be shy about the importance of investments to advance these advances," he said.
Baselga He had not been able to reveal millions Of dollars in payments of sanitary and pharmaceutical companies in articles of medical journals. In your letter of resignation., he he recognized his lapses and said that the controversy had turned out to be "too big a distraction".
Neither his resignation letter nor the hospital's statement about it suggested he was fired. But in his comments, Warner indicated that Baselga was expelled. "I have to say it's a tragedy, I liked Jose, I like José a lot," he said, "but unfortunately, José did not give us another option."
Baselga, one of the world's leading breast cancer researchers, also gave up advice from drug maker Bristol-Myers Squibb and Varian Medical Systems, a manufacturer of radiation equipment.
Christine Hickey, a hospital spokeswoman, said: "Dr. Baselga resigned, he was not fired. Mr. Warner pointed out that we had no choice but to accept his resignation. "
He also said that Warner and Thompson were referring not to their links to outside companies, but to a "compromise conflict."
"Dr. Baselga wanted to take on more, join more together, get involved in more external efforts," he said. "It was very widespread."
Memorial Sloan Kettering also announced at the end of last week that would limit the participation of its board members in new companies affiliated with the hospital, a development that followed the news of a Exclusive treatment of the hospital made with an artificial intelligence company. Founded by Memorial Sloan Kettering.
On Monday, Rep. Debbie Dingell, Democrat of Michigan, sent a letter Thompson, who seeks answers to a series of questions about the agreement with the company, Paige.AI, gives him the right to access images of 25 million tissue slides analyzed over decades. His letter questioned how the hospital planned to guarantee patient privacy, among other issues, many of which had been raised by hospital doctors at internal meetings once the agreement was made public.
Also on Monday, The New England Journal of Medicine posted a correction in two of Baselga's articles. The correction lists Baselga's relationships with 15 companies. A note from the editor attached to the correction reads: "Dr. Baselga did not disclose in these articles his multiple and substantial financial associations, which are now evident in the updated disclosure forms." When we learned of this abuse of trust, we conveyed our concern to the institution of Dr. Baselga, the Memorial Sloan Kettering Cancer Center. "
In his own comments to staff, Thompson apologized for what he described as his mismanagement of the recent crisis and said that Baselga had not acted appropriately.
"Jose informed me and I would like to have done more to keep him away from the line," Thompson said, according to the partial transcript of Monday's meeting. "While Dr. Baselga acknowledged his mistakes and resigned, this has not led to the closure of MSK. It has led to discussions about whether we still know where the right side of the line is. "
Warner, a former president of JPMorgan Chase & Company, acknowledged the "widespread anger" among staff members and that the hospital's reputation had been damaged.
"The question he is asking correctly is: Where the hell was the administration and the board of directors in all this? I should have protected this institution," Warner said. "The fact that you are angry has to do with the passion you feel for this place, the love you have for this place, the commitment you have with this place, and I would not have it in any other way."
Katie Thomas covers the pharmaceutical industry for The New York Times.
!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,'script',
'https://connect.facebook.net/en_US/fbevents.js');
fbq('init', '369524843414444');
fbq('track', 'PageView');
.
SOURCE LINK ERESVIRAL.COM https://www.beviral.online
Comentarios
Publicar un comentario